Page 44 - MDAnderson Memoria 2018
P. 44

Listado de ensayos clínicos iniciados en 2017
List of clinical trials started in 2017
   IMGN853-0403 (FORWARD1)
 FORWARD1: “A Randomized, Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator’s Choice of Chemotherapy in Adults with Folate Receptor α−positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Primary Fallopian Tube Cancer”
 Dr. Antonio González
 D0816C00014 (OReO)
 A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment
in Patients with Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy (OReO)
 Dra. Raquel Bratos
 A multicenter, open-label phase 1b/2 trial of levantinib (E7080) plus pembrolizumab in subjects with selected solid tumors
 Dra. Raquel Bratos
  Mtrap, Inc
  Safety and Performance of Metastatic Tumor Cell Trap Device in Patients with Advanced Ovarian Cancer
  Dr. Javier de Santiago
 TAKEDA (Millenium)
 A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy
 Dra. Pilar López Criado
 WO30070 (IMvigor)
Estudio de Fase III multicéntrico, randomizado, controlado con placebo de atezolizumab en monoterapia y en combinación con QT basada en platino en pacientes con carcinoma urotelial localmente avanzado o metastásico no tratado previamente
Phase III study, multicenter, randomized, placebo controlled with atezolizumab in monotherapy and combined with platinum based QT in patients with locally advanced or previously untreated metastatic urothelial carcinoma
Dr. Enrique Grande
 CO-338-052 (TRITON2)
  Clovis Oncology
  A multicenter, open-label phase 2 study of rucaparib in patients with metastasic castration-resistant prostate cancer associated with homologous recombination deficiency
  Dr. José Ángel Arranz
 CO-338-063 (TRITON3)
 Clovis Oncology
 A multicenter, randomized, Phase 3 study of rucaparib versus physician`s choice as 2nd line treatment following androgen receptor directed therapy for patient with metastasic castration-resistant prostate cancer
 Dr. José Ángel Arranz
 BioClin Therapeutics, Inc.
 A Phase1b/2, Randomized,Double-Blind,Placebo- Controlled,Multicenter, Parallel-Group Study of B-701Plus Docetaxel Versus Placebo Plus Docetaxel in the Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinomain Subjects who have Relapsed After,or are Refractory to Standard Therapy
 Dra. Pilar López Criado

   42   43   44   45   46